SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001683168-22-002526
Filing Date
2022-04-12
Accepted
2022-04-12 09:57:19
Documents
34
Period of Report
2022-02-28

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q cnbx_i10q-022822.htm   iXBRL 10-Q 351027
2 CERTIFICATION cnbx_ex3101.htm EX-31.1 9994
3 CERTIFICATION cnbx_ex3102.htm EX-31.2 10076
4 CERTIFICATION cnbx_ex3201.htm EX-32.1 5100
5 CERTIFICATION cnbx_ex3202.htm EX-32.2 4926
  Complete submission text file 0001683168-22-002526.txt   1518816

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cnbx-20220228.xsd EX-101.SCH 11523
7 XBRL CALCULATION FILE cnbx-20220228_cal.xml EX-101.CAL 26656
8 XBRL DEFINITION FILE cnbx-20220228_def.xml EX-101.DEF 17037
9 XBRL LABEL FILE cnbx-20220228_lab.xml EX-101.LAB 117076
10 XBRL PRESENTATION FILE cnbx-20220228_pre.xml EX-101.PRE 85540
28 EXTRACTED XBRL INSTANCE DOCUMENT cnbx_i10q-022822_htm.xml XML 116430
Mailing Address #3 BETHESDA METRO CENTER SUITE 700 BETHESDA MD 20814
Business Address #3 BETHESDA METRO CENTER SUITE 700 BETHESDA MD 20814 877-424-2429
CNBX Pharmaceuticals Inc. (Filer) CIK: 0001343009 (see all company filings)

IRS No.: 203373669 | State of Incorp.: NV | Fiscal Year End: 0831
Type: 10-Q | Act: 34 | File No.: 000-52403 | Film No.: 22821315
SIC: 2834 Pharmaceutical Preparations